Format
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 5

1.

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernards R, Baselga J.

Cancer Res. 2008 Nov 15;68(22):9221-30. doi: 10.1158/0008-5472.CAN-08-1740.

2.

mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb).

Vázquez-Martín A, Oliveras-Ferraros C, del Barco S, Martín-Castillo B, Menéndez JA.

Clin Transl Oncol. 2009 Jul;11(7):455-9. Review.

PMID:
19574203
3.

[PI3K and mTOR pathway and molecular targeted agents].

Nishio K, Sakai K, Togashi Y.

Nihon Rinsho. 2015 Aug;73(8):1315-22. Review. Japanese.

PMID:
26281684
4.

The PIK3CA gene as a mutated target for cancer therapy.

Gustin JP, Cosgrove DP, Park BH.

Curr Cancer Drug Targets. 2008 Dec;8(8):733-40. Review.

5.

Kinase inhibitors of marine origin.

Bharate SB, Sawant SD, Singh PP, Vishwakarma RA.

Chem Rev. 2013 Aug 14;113(8):6761-815. doi: 10.1021/cr300410v. Epub 2013 May 16. Review. No abstract available.

PMID:
23679846
Format
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk